

6 November 2006

IMMUNODIAGNOSTIC SYSTEMS HOLDINGS PLC
Unaudited Interim Results for the Six-Month Period to 30 September 2006

Immunodiagnostic Systems Holdings plc ("IDS" or the "Company"), a leading producer of diagnostic testing kits for the clinical and research markets, announces its interim results for the six month period to 30th September 2006.

IDS operates in the in-vitro diagnostics ("IVD") market. The Company designs, manufactures and sells immunoassay kits which are used to measure or detect particular substances within a sample, thus aiding the diagnosis or monitoring of a disease or providing information for research studies. In 2002 the immunoassay sector of the IVD market was estimated to be worth US\$ 3.9bn.

Financial Highlights

- Turnover up 22% to £4.53m (2005: £3.72m).
- EBITA up 58% to £811,000 (2005: £514,000).
- Operating Profit up 78% to £777,000 (2005: £436,000).
- Pre-tax profit up 90% to £737,000 (2005: £387,000).

Operational Highlights

- IDS benefiting from direct distribution networks established in US and Germany and France.
- Establishment of an Austrian operation in September of this year.
- Successful automation of IDS products onto semi-automated platforms.
- IDS received the Queens Award for Export in April of this year.

In his statement to shareholders, David Evans, Chairman, said:

"The outlook for the Group for the second half remains very positive and trading continues to exceed expectation.

"I see continued growth being achieved across all aspects of the Group's business and the challenges for the Group at this moment in time are positive ones.

"I look forward to updating you further as we make further progress and in particular in relation to the Group's plans for automation and the strengthening of the management team."

Contacts:

IDS

Roger Duggan,
Managing Director
Tel: 0191 519 0660
<http://www.ids-direct.com>

Paul Hailes,
Finance Director
Tel: 0191 519 0660

Parkgreen Communications Ltd

Paul McManus
Tel: 020 7493 3713
Mob: 07980 541 893

CHAIRMAN'S STATEMENT

Dear Shareholder

I have pleasure in reporting to you the interim results of Immunodiagnostic Systems holdings plc for the six month period ended 30th September 2006. It has been a period of considerable progress for the Group and I have outlined below the highlights of the period.

Results:

Turnover for the Group amounted to £4.53m, which when compared to same period last year represents a 21.9% increase. Our core products continue to see sales growth, both domestically and abroad. The Gross margin percentage declined by 1% as a result of a different product mix year on year. Other costs rose 10% which were in line with expectation.

This has resulted in an EBITA of £811,000 (2005:£514,000) an Operating Profit of £777,000 (£436,000) with a Profit before Tax of £737,000 (2005:£387,000) and after tax of £600,000 (2005: £324,000.) The Company paid its first dividend during the period amounting to £133,000 (2005:£nil) resulting in an overall net profit for the period of £467,000(2005: £324,000).

Business Overview

The Group has continued to grow and is benefiting from its direct sales into both the USA and our key European territories of Germany, France and the United Kingdom. This ability to access key markets represents a sound foundation stone and this access was extended in September with the establishment of our Austrian operation which can be directly supported infrastructurally from Germany. The overall successful growth of turnover in markets beyond the UK was recognised in April with the Queen's Award for Export.

The success of the establishment of our French subsidiary in a short space of time is particularly pleasing as has been the Group's determined approach to ensuring that major accounts in the UK have the option to have the IDS products on an automated platform.

The challenge of automating our tests is one that represents a major opportunity for the company to ensure the valuable know-how and patented products can be exploited globally without revenue and margin erosion. Management has worked hard at seeking a global cost effective solution and we shall update you when contracts are finalised. This will require modest additional investment in R&D and this will be achieved internally without impacting future profitability.

The move to greater automation has major potential but it will occupy our existing R&D commitment going forward and consequentially there is a greater motivation to source new products externally.

Board Management and Team

It was with regret that Dr Philip Lee our Technical Director left to return to the USA. We have been searching for a suitable replacement and anticipate making an announcement shortly. We are also hoping to strengthen our executive management team further to cope with the anticipated increased throughput as the Group moves to its next stage of development.

Outlook

The outlook for the Group for the second half remains very positive and trading continues to slightly exceed expectation.

I see continued growth being achieved across all aspects of the Group's business and the challenges for the Group at this moment in time are positive ones.

I look forward to updating you further as we make further progress and in particular in relation to the Group's plans for automation and the strengthening of the management team.

David Evans
6 November 2006

Unaudited consolidated Profit and Loss Account

For the six month period to 30 September 2006

	Note	6 Months ended 30 Sept 2006 £'000	6 Months ended 30 Sept 05 £'000	Year ended 31 March 2006 £'000
Turnover	2	4,533	3,717	8,133
Cost of Sales		(1,613)	(1,282)	(2,885)
<hr/>				
Gross Profit		2,920	2,435	5,248
Administrative expenses		(2,143)	(1,999)	(3,993)
<hr/>				
Operating Profit		777	436	1,255
Share of operating profit / (loss) in associates		0	(16)	(12)
Net interest (payable) / receivable		(40)	(33)	(69)
<hr/>				
Profit on ordinary activities before taxation	2	737	387	1,174
Tax on profit on ordinary activities	6	(137)	(63)	(257)
<hr/>				
Profit for the period		600	324	917
<hr/>				
Earnings per share				
- basic (per share pence)	5	4.496	2.428	6.871
- diluted (per share pence)	5	4.496	2.428	6.871

No separate Statement of Total recognised Gains and Losses has been presented as all such gains and losses have been dealt with in the Profit and Loss account.

Unaudited consolidated Balance Sheet

As at 30 September 2006

	Note	6 Months ended 30 Sept 2006 £'000	6 Months ended 30 Sept 2005 £'000	Year ended 31 March 2006 £'000
Fixed Assets				
Intangible Assets		1,058	1,016	1,094
Tangible Assets		964	764	746
Investments		2	1	2
		<hr/>	<hr/>	<hr/>
		2,024	1,781	1,842
Current Assets				
Stocks		935	837	805
Debtors		1,478	1,210	1,563
Cash at bank and in hand		840	603	885
		<hr/>	<hr/>	<hr/>
		3,253	2,650	3,253
Creditors – Amounts falling due within one year		1,438	1,593	1,664
		<hr/>	<hr/>	<hr/>
Net current assets		1,815	1,057	1,589
		<hr/>	<hr/>	<hr/>
Total assets less current liabilities		3,839	2,838	3,431
		<hr/>	<hr/>	<hr/>
Creditors – Amounts falling due after one year		351	496	441
		<hr/>	<hr/>	<hr/>
Provisions for liabilities and charges		122	287	122
		<hr/>	<hr/>	<hr/>
Net assets		3,366	2,055	2,868
		<hr/>	<hr/>	<hr/>
Capital and reserves				
Called up share capital	8	267	267	267
Profit and loss account		1,582	497	1,084
Other Reserve	9	1,519	1,523	1,519
Own Shares		(2)	(232)	(2)
Shareholders' funds	7	3,366	2,055	2,868
		<hr/>	<hr/>	<hr/>

Unaudited consolidated Cash Flow Statement

For the six month period to 30 September 2006

	Note	6 Months ended 30 Sept 2006 £'000	6 Months ended 30 Sept 2005 £'000	Year ended 31 March 2006 £'000
Net cash inflow / (outflow) from operating activities	10	708	534	1,216
Returns on investments and servicing of finance		(40)	(33)	(69)
Interest paid				
Taxation		(138)	0	(128)
Capital expenditure				
Purchase of tangible fixed assets		(310)	(147)	(133)
Purchase of intangible fixed assets		0	(69)	(158)
Dividends Paid		(133)	0	0
Net cash inflow / (outflow) before use of liquid resources and financing		87	285	728
Financing				
Net increase / (decrease) in Bank loans		(132)	(88)	(226)
Capital element of hire purchase		0	(12)	(61)
Funds from Share Issue		0	(26)	0
Net cash inflow from financing		(132)	(126)	(287)
Increase / (Decrease) in cash		(45)	159	441
Reconciliation of net cash flow to movement in net debt				
(Decrease) / Increase in Cash in the period		(45)	159	441
Net Cash inflow / (outflow) from bank loans		132	88	195
Net cash outflow in respect of hire purchase		0	(69)	61
New hire purchase		0	0	(170)
Increase / (decrease) in net funds rising from cash flows		87	178	527

Notes to the Interim Financial Statements

For the period to 30 September 2006

1 This interim statement for the six month period to 30 September 2006 is unaudited and was approved by the Directors on 3rd November 2006. The information set out does not constitute statutory accounts within the meaning of Section 240 of the Companies Act 1985.

2 Turnover and profit before taxation were all derived from the Group's principal activities.

3 The Group's accounting policies are consistent with those of the subsidiaries for the previous financial year and with those set out in the Prospectus with the exception of the basis of consolidation (see Note 4).

4 Basis of consolidation

The consolidated financial information incorporates the financial information relating to the Company and the consolidated results of its subsidiary undertaking, Immunodiagnostic Systems Limited, using the merger method of accounting.

The consolidated financial information relating to Immunodiagnostic Systems limited and its subsidiary undertakings was prepared using the acquisition method of accounting and includes Immunodiagnostic Systems Limited's share of the results and net assets of its associates.

5 Earnings per share

Earnings per share for the period ended 30 September 2006 has been calculated using the average number of ordinary shares in issue since 1 April 2006 of 13,344,667, less own shares held by the IDS Employee Benefit Trust.

6 Taxation

Taxation for the 6 months ended 30 September 2006 is based on the effective rate of taxation which is estimated to apply to the year ended 31 March 2007.

7 Reconciliation of Movement in Group Shareholder's Funds

	6 Months to 30 Sept 2006 £'000	6 months to 30 Sept 2005 £'000	Year ended 31 Mar 2006 £'000
Profit for the period	600	324	917
Foreign exchange translation differences on foreign currency net investment in subsidiaries.	31	(4)	(10)
Movement in other reserve	0	(26)	200
Dividend Paid	(133)	0	0
Net change in shareholders' funds	498	294	1,107
Shareholders' funds at the beginning of the period	2,868	1,761	1,761
Shareholders' funds at the end of the period	3,366	2,055	2,868

8 Share Capital

	6 Months 30 Sept 2006 £	6 months to 30 Sept 2005 £	Year ended 31 Mar 2006 £
Authorised: 50,000,000 ordinary 2p shares	1,000,000	1,000,000	1,000,000
	<hr/> 1,000,000	<hr/> 1,000,000	<hr/> 1,000,000
Alotted, called up and fully paid: 13,344,667 ordinary 2p shares	266,913	266,913	266,913
	<hr/> 266,913	<hr/> 266,913	<hr/> 266,913

9 Other reserve

The other reserve arises on consolidation of the results of Immunodiagnostic Holdings PLC and the consolidated results of Immunodiagnostic Systems Limited. The reserve represents the difference arising on consolidation between the nominal value of shares issued by Immunodiagnostic Holdings PLC in consideration for 100% of the share capital of Immunodiagnostic Systems Limited and the nominal value of the shares acquired, plus the share premium account relating to those shares.

10 Reconciliation of Operating Profit to Net Cash Flow from Operating Activities

	6 Months to Sept 2006 £'000	6 months to Sept 2005 £'000	Year ended 31 March 2006 £'000
Reconciliation of operating profit to net cash outflow from operating activities			
Operating profit	777	436	1,255
Depreciation and amortisation	128	168	286
Increase in stock	(130)	(74)	(43)
(Increase) / Decrease in debtors	85	61	(291)
Decrease in creditors	(152)	(30)	9
Decrease in provisions	—	(27)	—
	<hr/>	<hr/>	<hr/>
Net cash inflow from operating activities	708	534	1,216

11 Report and Financial Statements

The comparative figures for the financial year ended 31 March 2006 have been extracted from the Group's statutory financial statements for that financial year. Those financial statements have been reported on by the Group's auditors and delivered to the Registrar of Companies. The report of the auditors was unqualified and did not contain a statement under section 237 (2) or (3) of the Companies Act 1985. Copies of the Annual Report for 2005 are available from the Company's registered office by applying to the Company Secretary.

The interim results for the six months ended 30th September 2006 and 30th September 2005 have not been audited. The financial information set out above does not constitute full financial statements as defined by section 240 of the Companies Act 1985.

Company: Name: Immunodiagnostic Systems Holdings PLC

Address: 10 Didcot Way
Boldon Business Park
Boldon
Tyne & Wear
NE35 9PD

Board of Directors:

David Eric Evans	Non-Executive Chairman
Dr Roger Thomas Duggan	Managing Director
Paul Hailes	Finance Director
William Michael Dracup	Non- Executive Director
Dr Edward Duncan Blair	Non- Executive Director

Company Secretary: Paul Hailes

Nominated Advisor and Broker: Teather and Greenwood
Beufort House
15 Botolph Street
London
EC3A 7QR

Auditors: Baker Tilly
1 St James' Gate
Newcastle Upon Tyne
NE1 4AD

Registrars: Computershare Investor Services Plc
Corporate Actions PO Box 859
The Pavilions
Bridgewater Road
Bristol
BS99 1XZ

Solicitors: Shepherd and Wedderburn
155 St Vincent Street
Glasgow
G2 5NR

Bankers: HSBC Bank Plc
110 Grey Street
Newcastle Upon Tyne
NE1 6JG